HLA-C and neoplasm: The NGS technology first detects the abnormal mutation sites in the tumor cells, and then combines the molecular characteristics of Major Histocompatibility Complex (MHC) to screen the mutant proteins with high binding potential to MHC, which can accurately predict the neoantigens that can be used for the reatment [117–120](Fig. 4).